New TB vaccines could change the course of the epidemic, saving millions of lives and reducing long-term costs. The current Bacille Calmette-Guérin (BCG) vaccine is over 100 years old and offers limited protection for adolescents and adults, who are most at risk.
After decades of research, several new vaccine candidates are in final trials, with results expected in 2027 and 2028. Early preparation for roll-out will be key to ensuring access that is timely, equitable and affordable.
Informed by an expert panel of scientists, policymakers and people with lived experience, a brief, released by the Global TB Caucus, outlines what good vaccine preparedness looks like and how parliamentarians can drive early action.
Access the brief here. An executive summary is available in English, Spanish ans Russian.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #35, 17 November 2025).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Global TB Caucus
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.